BriovaRx Infusion Services

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, BriovaRx Infusion Services sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).

3 total trials none currently recruiting 1 completed upper quartile by trial count

BriovaRx Infusion Services: 3 sponsored US clinical trials, none currently recruiting.

BriovaRx Infusion Services sponsors 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 1 completed. The most-studied condition in this pipeline is Primary Immunodeficiency Disease (PIDD), with 1 trials.

Upper-quartile sponsor footprint

BriovaRx Infusion Services sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

How the BriovaRx Infusion Services archive is shaped

3 indexed studies, none listed as recruiting (0% open); 1 completed (33%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Primary Immunodeficiency Disease (PIDD) (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

BriovaRx Infusion Services: archived-pipeline peers nationwide

Peers matched on 3 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

BriovaRx Infusion Services sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%0.0%0.0%0.1% Total trials Recruiting share BriovaRx Infusion Services10xBio22nd Century GroupAA SecordAAADRS Clinical Research Center23andMe3-C Institute for Social Development3 Waves Wellness3EO Health
BriovaRx Infusion Services sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

BriovaRx Infusion Services sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 3 archived trials

Sponsors with similar archive density (± trial count)

What to do with this BriovaRx Infusion Services page

3 registered trials is a research-attention snapshot, not an endorsement of BriovaRx Infusion Services or any single study.

  • None of BriovaRx Infusion Services's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Primary Immunodeficiency Disease (PIDD) is the condition BriovaRx Infusion Services studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Primary Immunodeficiency Disease (PIDD) trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. BriovaRx Infusion Services pipeline card: 3 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.